Chronic liver disease is a rapidly growing cause of morbidity and mortality worldwide, and this increase is largely driven by steatotic liver disease (SLD) comprising metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and MASLD and increased alcohol intake (MetALD). Hepatic steatosis and fibrosis are highly heritable and genetic variation has also been associated with the risk of hepatocellular carcinoma (HCC) and hepatic decompensation. This review summarizes the state of the art of genetics and genomics in SLD, with particular emphasis on potential clinical utility. Variants in/near genes including PNPLA3, TM6SF2, and HSD17B13 have been associated with cirrhosis and HCC in both MASLD and ALD, while others such as those in GCKR, TRIB1, and GPAM have been consistently associated with greater risk of hepatic steatosis in MASLD with much weaker effects if any on cirrhosis and HCC. While data on MetALD genetics are limited, we believe that the genetic risk factors for liver steatosis, cirrhosis, and HCC will be similar in MetALD compared to MASLD and ALD based on the largely shared genetic risk factors for MASLD and ALD. Finally, we discuss future directions in SLD genetics, notably genetically-defined disease subtypes, gene-environment interactions and their implications for therapy, and the utility of genetics in clinical risk stratification. Genetic studies have provided insight into important disease processes in SLD and may have an upcoming role in clinical care.
Citations
Citations to this article as recorded by
Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies Qin Tang, Jiahui Li, Haiying Song, Ailin Zhang, Haifeng Zeng, Yining Xu, Li Mo, Jinhan He Advanced Science.2026;[Epub] CrossRef
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five‐Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Seung Up Kim, Su Jong Yu, Pil Soo Sung Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Alcohol-aware risk stratification and subtype-specific care pathways across metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Hyo Young Lee, Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0659. CrossRef
Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.1072. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Outcomes in Atrial Fibrillation Pojsakorn Danpanichkul, Yanfang Pang, Kwanjit Duangsonk, Nithila Sivakumar, Primrose Tothanarungroj, Ahmad Anouti, Matheus Souza, Omar Y. Mousa, Thomas G. Cotter, Donghee Kim, Suthat Liangpunsakul, Chayakrit Krittanawong, Mazen Noureddin The American Journal of Medicine.2026;[Epub] CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(2): e194. CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Gut and Liver.2026; 20(5): 728. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Outcomes in Atrial Fibrillation Pojsakorn Danpanichkul, Yanfang Pang, Kwanjit Duangsonk, Nithila Sivakumar, Primrose Tothanarungroj, Ahmad Anouti, Matheus Souza, Omar Y. Mousa, Thomas G. Cotter, Donghee Kim, Suthat Liangpunsakul, Chayakrit Krittanawong, Mazen Noureddin The American Journal of Medicine.2026;[Epub] CrossRef
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0444. CrossRef
Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016–2020 Angela T. Estadt, Hasan Symum, William W. Thompson, Taiwo O. Abimbola, Michelle Van Handel American Journal of Preventive Medicine.2026; : 108417. CrossRef
Association of documented social deprivation with cardiovascular and liver outcomes in alcohol-associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Andrew F. Ibrahim, Supapitch Sirimangklanurak, Allan Bueso, Daniel M. Simadibrata, Shu-Yen Chan, Karn Wijarnpreecha, Mazen Noureddin, Donghee Kim, Suthat Liangpunsakul Alcohol.2026; 132: 24. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Association of a Reported Penicillin Allergy Label With Clinical Outcomes in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Kanyaphak Charnpatanakorn, Preenapun Saokhieo, Ben Thiravetyan, Allan Bueso, Ahmad Anouti, Apichat Kaewdech, Surapon Nochaiwong, Luis Antonio Díaz, Juan Pablo Arab, Jonathan A. Bernstein, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Reply to correspondence 1 on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States” Sung-Eun Kim Clinical and Molecular Hepatology.2026; 32(1): e125. CrossRef
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Contemporary global epidemiology of cirrhosis Preenapun Saokhieo, Thanida Auttapracha, Pojsakorn Danpanichkul, Yanfang Pang, Liu Yang, Amit G. Singal, Donghee Kim, Karn Wijarnpreecha Hepatology Communications.2026;[Epub] CrossRef
Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver out Donghee Kim, Anoushka Shenoy, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(3): 1441. CrossRef
Chronic Liver Disease–Related Mortality Among Hispanic Subpopulations in the United States Between 2018 and 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Gut and Liver.2026; 20(5): 728. CrossRef
Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023 Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e277. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol 2025;31(3):1058-1070. Published online April 11, 2025
Background/Aims Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021.
Methods Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US.
Results In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the US. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (annual percent change [APC] 2.21%, 95% confidence interval [CI] 1.70–2.73%) and other pharyngeal cancer (APC 1.35%, 95% CI 1.08–1.62%).
Conclusions The burden of ALD is substantial and continues to rise in the US, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcoholattributable extrahepatic malignancies.
Citations
Citations to this article as recorded by
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2026; 8(1): 101646. CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha Digestive Diseases and Sciences.2026; 71(6): 2165. CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Spatiotemporal trends, demographic disparities, and predictions to 2040 in gastrointestinal cancer mortality in the United States Maolang He, Jingyi Zhang, Shangqi Wang, Kainan Xing, Yanxin Zhao, Jianzhen Chen, Xi Zhang, Yong Zheng, Shuxin Tian BMC Public Health.2026;[Epub] CrossRef
Global burden of esophageal cancer attributable to smoking and alcohol, 1990–2021, with projections to 2040: a population-based analysis of the global burden of disease study 2021 Hui Zhou, Jiao Wu, Yuan Yin Annals of Medicine.2026;[Epub] CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
History of Alcohol‐Related Cancers and ADH1B/ALDH2 Genotypes in a Large Japanese Cohort of Male Patients With Alcohol Dependence Akira Yokoyama, Tetsuji Yokoyama Cancer Medicine.2026;[Epub] CrossRef
Alcohol-attributable cancer mortality in the United States, 1990–2023: a secondary analysis of Global Burden of Disease data Chinmay T. Jani, Kyle Edwards, Rajesh Sharma, Ruchi T. Jani, Ali Al Sbihi, Jose Noy, Georges Chedid, Samuel Kareff, Joseph Shalhoub, Justin Salciccioli, Dionysios C. Watson, Aman Chauhan, Estelamari Rodriguez, Gilberto Lopes The Lancet Regional Health - Americas.2026; : 101599. CrossRef
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0444. CrossRef
MetALD: new insights and unraveling therapeutic potential Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul Liver International.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Alcohol use and cirrhosis in women: An underestimated risk P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef
Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma Michelle Ng, Olgert Bardhi, Krystal Lai, Eden Koo, Sruthi Yekkaluri, Kevin Bass, Guruveer Bhamra, Pojsakorn Danpanichkul, Lisa Quirk, Ju Dong Yang, Jeremy Louissaint, Thomas A. Kerr, Amit G. Singal BMC Gastroenterology.2025;[Epub] CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu Free Radical Biology and Medicine.2025; 240: 693. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab
Clin Mol Hepatol 2025;31(2):525-547. Published online January 9, 2025
Background/Aims Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.
Methods We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
Results In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Conclusions Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
Citations
Citations to this article as recorded by
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2026; 8(1): 101646. CrossRef
Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US Mai Sedki, Zeyuan Yang, Ashwani K. Singal, Mário Guimarães Pessoa, Aleksander Krag, Jörn M. Schattenberg, Linda Henry, Saleh Alqahtani, Jeffrey V. Lazarus, Zobair M. Younossi, Robert J. Wong JHEP Reports.2026; 8(3): 101680. CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha Digestive Diseases and Sciences.2026; 71(6): 2165. CrossRef
An Integrated Systematic Review and Meta‐Analysis From the Bloodstream to Identify Potential Biomarkers for ALD, MASLD, and HCC Without a Viral Background Karina González‐García, Cecilia Zertuche‐Martínez, Itayetzi Reyes‐Avendaño, Edilburga Reyes‐Jiménez, Pablo Muriel, Saúl Villa‐Treviño, Jaime Arellanes‐Robledo, Rafael Baltiérrez‐Hoyos, Verónica Rocío Vásquez‐Garzón Journal of Gastroenterology and Hepatology.2026; 41(2): 502. CrossRef
Liver–pancreas communication in disease and drug development Yan Jia, Qingtian Zhu, Qiong Pan, Guotao Lu, Jia Xiao Acta Pharmaceutica Sinica B.2026; 16(3): 1250. CrossRef
Beyond Stigma–Integrating Neurobiology, Genetics, and Awareness Integration Theory in Addiction Recovery Kenneth Blum, Mark Gold, Nicole Jafari, Kai-Uwe Lewandrowski, Alireza Sharafshah, Kavya Mohankumar, Morgan Lorio, Abdalla Bowirrat, Albert Pinhasov, Kyriaki Thanos, Igor Elman, David Baron, Catherine Dennen, Brian Fuehrlein, Alexander Lewandrowski, Edward Psychology Research and Behavior Management.2026; Volume 19: 1. CrossRef
Efficacy of Probiotic Treatment in Alcoholic Liver Disease: A Systematic Review of Animal Studies Konrad Sosnowski, Robert Kucharski, Adam Przybyłkowski Nutrients.2026; 18(4): 608. CrossRef
Gomphus floccosus (Schw.) Sing. extract attenuates alcoholic liver disease by suppressing macrophage glycolysis and M1 polarization Tianyin Ruan, Xutao Li, Mingyue Li, Siyuan Wang, Li Shen, Chenghai Liu, Yuan Peng, Yanyan Tao Frontiers in Immunology.2026;[Epub] CrossRef
Impact of gastrectomy on the risk of alcohol-associated liver disease in patients with gastric cancer Sang Yi Moon, Yang Hyun Baek, Dongwoo Kang, Jungkuk Lee, Yeo Wool Kang, Minkook Son, Hongqun Liu, Samuel S. Lee, Junho Park Scientific Reports.2026;[Epub] CrossRef
Association of documented social deprivation with cardiovascular and liver outcomes in alcohol-associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Andrew F. Ibrahim, Supapitch Sirimangklanurak, Allan Bueso, Daniel M. Simadibrata, Shu-Yen Chan, Karn Wijarnpreecha, Mazen Noureddin, Donghee Kim, Suthat Liangpunsakul Alcohol.2026; 132: 24. CrossRef
MetALD: A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease Butros Fakhoury, Ivonne Hurtado Díaz de León, Krishan S. Patel, Luis Antonio Díaz, Juan Pablo Arab Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
The Acetylcholine Esterase Inhibitor Donepezil Increases Dopamine Levels in the Nucleus Accumbens and Blocks the Alcohol Deprivation Effect in Rats Anna Loftén, Klara Danielsson, Louise Adermark, Bo Söderpalm, Mia Ericson Addiction Biology.2026;[Epub] CrossRef
MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism.2026; 37(9): 815. CrossRef
Alcohol-Consumption Animal Models in Neurological Disease Research: A Review of Development, Current Status, and Prospects Biyun Cao, Rong Zhang, Yalang Deng, Yuxin Wang, Shiyun Jin Neuropharmacology and Therapy.2026;[Epub] CrossRef
The emerging role of FGF21 in alcohol consumption and dependence: mechanisms and therapeutic prospects Simranpreet Kaur, Khadga Raj Aran Gene.2026; 997: 150150. CrossRef
The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression Xin-Zhou Sun, Yan Liu Viruses.2026; 18(4): 473. CrossRef
Hepatocyte CEBPA-ORM1 axis restricts alcohol-associated liver disease Nana Yan, Yangliu Xia, Yang Zhang, Vorthon Sawaswong, Xi Xu, Yoshifumi Saito, Ravikanth Nanduri, Mengge Dai, Daisuke Aibara, Kristopher W. Krausz, Shogo Takahashi, Brandon J. Peiffer, Maria A. Parra, Zhaoli Sun, Haiping Hao, Tingting Yan, Frank J. Gonzale Hepatology.2026;[Epub] CrossRef
Serum HMGB1 and Alcohol-Related Liver Disease Iwona Popiolek, Piotr Hydzik, Krzysztof Ciszowski, Barbara Balicka-Slusarczyk, Ewa Gomolka, Beata Szkolnicka, Lubomir Skladany, Juan Pablo Arab, Ivica Grgurevic, Michal Kukla Journal of Clinical Medicine.2026; 15(9): 3397. CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study Anna Loften, QuanQiu Wang, Mehdi Farokhnia, David C. Kaelber, Nora D. Volkow, Leandro F. Vendruscolo, Rong Xu, Lorenzo Leggio Psychopharmacology.2026;[Epub] CrossRef
Small extracellular vesicles in alcohol use disorders: a scoping review Vsevolod V. Severtsev, Emilia R. Kamalieva, Elena Yuryevna Sklyar, Anastasia R. Pevunova, Elizaveta V. Finko, Milyausha Sh. Galeeva, Nikolay N. Ivanets Consortium PSYCHIATRICUM.2026; 7(2): 60. CrossRef
Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe Elisa Pose, Luis Antonio Díaz, Richard Parker, Mads Israelsen, Thomas Marjot, Ewan Forrest, Ashwin Dhanda, Catherine Paradis, Juan Pablo Arab, Aleksander Krag, Ramón Bataller, Frank Murray, Jeffrey V. Lazarus, Patrizia Carrieri, Paul N. Brennan The Lancet Regional Health - Europe.2026; 65: 101707. CrossRef
“In Vino Veritas, in Aqua Sanitas”: A Mixed-method Study to Explore the Factors of Alcohol Relapse Using Q-Methodology Roji Moni Borah, Mini George Gastroenterology Nursing.2026; 49(3): 147. CrossRef
Research on the Highly Efficient and Low-Dose Improvement of Alcohol-Induced Liver Injury by High-Selenium-Content Modified Lycium barbarum Polysaccharides Shuangzhe Mao, Xin Zhang, Lulu Wei, Han Zhang, Abo Li, Mengmeng Sun, Jiao Feng, Ting Ren, Yiting Huang, Xiaoying Liu, Zhifeng Zhang, Zhihui Zhao, Jianfang Dong, Kangning Wu, Youli Ma, Hongbin Mi, Zhongqiu Hu Biological Trace Element Research.2026; 204(9): 7070. CrossRef
Assessing alcohol consumption in an era of direct alcohol markers Cecilia Jönsson, Mattias Ekstedt, Patrik Nasr JHEP Reports.2026; 8(9): 101906. CrossRef
Exploring the roles of genes associated with leukocyte transendothelial migration in liver cirrhosis development Lei Feng, Jiao He, YanLing Mu, Jie Liu, Yong Yao, Junzheng Yang PLOS One.2026; 21(6): e0350886. CrossRef
Steatotic liver disease in Latin America: current views and perspectives Francisco Idalsoaga, Luis Antonio Díaz, Francisco Barrera, Adrian Gadano, Claudia P. Oliveira, Juan Pablo Arab, Marco Arrese Nature Reviews Gastroenterology & Hepatology.2026; 23(9): 722. CrossRef
Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Daisuke Yokoyama, Takatsugu Tanaka, Akimitsu Meno, Takuya Sho, Risako Kohya, Ruixin Deng, Qingjie Fu, Zijian Yang, Osamu Maehara, Shunsuke Ohnishi, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Tatsuhiko K Journal of Gastroenterology.2026; 61(10): 1460. CrossRef
The changing epidemiology of primary liver cancer in the 21st century Shahid A. Khan, Mathew Vithayathil, Terry C.F. Yip, Hashem B. El-Serag Journal of Hepatology.2026; 85(4): 656. CrossRef
The Role of FGF1 in Chronic Liver Diseases Tao Liu, Meihong Yu, Liu Han, Jing Wu, Deliang Liu, Yuyong Tan Biomedicines.2026; 14(7): 1436. CrossRef
History of Alcohol‐Related Cancers and ADH1B/ALDH2 Genotypes in a Large Japanese Cohort of Male Patients With Alcohol Dependence Akira Yokoyama, Tetsuji Yokoyama Cancer Medicine.2026;[Epub] CrossRef
Contemporary global epidemiology of cirrhosis Preenapun Saokhieo, Thanida Auttapracha, Pojsakorn Danpanichkul, Yanfang Pang, Liu Yang, Amit G. Singal, Donghee Kim, Karn Wijarnpreecha Hepatology Communications.2026;[Epub] CrossRef
Thyroid disease–attributed mortality burden and temporal trends among U.S. adults aged ≥65 years, 1999–2023: a nationwide analysis based on the CDC WONDER database Jiadi Li, Zide Chen Frontiers in Public Health.2026;[Epub] CrossRef
The Effects of Transcranial Magnetic Stimulation on Alcohol Craving, Efficacy, Emotion, and Cognitive Function in Patients With Alcohol Use Disorders: A Systematic Review and Meta‐Analysis of Randomized Controlled Trial Jiayuan Song, Xingchen He, Ji Ouyang, Zhaoying Li, Yanlin liu, Han Yu, Aimin Li, Hongwei Liu, Haixia Fan, Fan Yao Brain and Behavior.2026;[Epub] CrossRef
Prognostic significance of prior alcohol use disorder in patients with presumed metabolic dysfunction‐associated steatotic liver disease: A large multi‐center cohort study Butros Fakhoury, Jinye Liu, Vinay Jahagirdar, Kaanthi Rama, Gerald Scott Winder, Luis Antonio Díaz, Juan Pablo Arab Addiction.2026;[Epub] CrossRef
Long-term trends and future projections of cancer incidence and mortality in the upper central region of Thailand, 2000–2040 Saksin Simsin, Siriporn Kamsa-ard, Supot Kamsa-ard, Atit Leklob, Surin Uadrang, Apiporn Thinkhamrop Suwannatrai, Prapassara Sirikarn Cancer Epidemiology.2026; 104: 103194. CrossRef
The impact of alcohol consumption on the risk of hepatocellular carcinoma across different age groups: A nationwide cohort study Mi Na Kim, Kyungdo Han, Dong Yun Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim JHEP Reports.2026; 8(10): 101975. CrossRef
Epidemiology of Alcohol-Associated Hepatitis: A Systematic Review of Population-Based Studies Jakub Gazda, Tomas Koky, Aleksandra Robinska, Na Bo, Einar Stefan Bjornsson, Sylvia Drazilova, Martin Janicko, Luis Antonio Díaz, Fisher Rhoads, Peter Jarcuska, Juan Pablo Arab Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications Luis Antonio Díaz, Elisa Pose, Mads Israelsen, Rohit Loomba Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Neighbourhood Deprivation Is Associated With Greater Mortality in Patients With Alcohol‐Associated Liver Disease Leith Ghani, Claire S. Faulkner, Majd B. Aboona, Pradhan Hariharan, Pooja Rangan, Amal Altaf, David O. Garcia, Vincent L. Chen, Donghee Kim, Juan Pablo Arab, Mazen Noureddin, Luis Antonio Díaz, Ani Kardashian, Michael B. Fallon, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
From allostasis to addiction: Cortisol dysregulation, daily stress and relations with 9‐year alcohol and substance use disorder severity in community adults Nur Hani Zainal, Natalia Van Doren Addiction.2026;[Epub] CrossRef
Alcohol-related liver disease and access to liver transplantation: where we stand and where we should go Inês Mega, Eloisa Franchi, Giacomo Germani, Hermien Hartog, Speranta Iacob, Phillipe Mathurin, Silvio Nadalin, Stephen Potts, Giuliano Testa, Luca Saverio Belli Transplant International.2026;[Epub] CrossRef
Preventive effects of Faecalibacterium prausnitzii on chronic alcoholic liver injury and associated alterations in gut microbiota and host phenotypes in mice Rui Guo, Tao Zhang, Fangfang Li Journal of Applied Microbiology.2026;[Epub] CrossRef
Impact of Addiction Consult Service on Alcohol Use Disorder Medications and Postdischarge Outcomes Thomas J. Reese, Kristopher A. Kast, David Marcovitz, Clayton Korson, Hilary A. Tindle, Sahit N. Menon, Ashley A. Leech, Lisa Stewart-Kast, Adam Wright, Mauli V. Shah, Amanda von Horn Journal of Addiction Medicine.2026;[Epub] CrossRef
Blocking the gut–liver IgA axis attenuates macrophage-mediated inflammation and injury in alcohol-associated liver disease Min Gu Kim, Kwon Yong Tak, Deok Hwa Seo, Gil Won Lee, Sung Woo Cho, Mi Hyun Kwon, Sung Hak Lee, Eui Soo Han, Jae Yong Ryu, Hee Sun Cho, Keung Mo Yang, Ji Won Han, Jeong Won Jang, Ki Young Choi, Pil Soo Sung Gut.2026; : gutjnl-2026-338715. CrossRef
TRAIP Mediates Alcohol‐Induced Liver Injury through Regulating β‐catenin Ubiquitin Degradation via Direct Interaction Zhan Wu, Mingjiang Liu, Lijuan Liao, Zhaohong Mo, Wenli Xu, Linfeng Mao, Yubing Chen, Qiuli Xie, Ming Yao, Shilian Chen, Stephen Tomlinson, Sebastian Mueller, Songqing He, Guandou Yuan Advanced Science.2026;[Epub] CrossRef
Detection of Potential Metabolic and Alcohol–Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction–Associated Steatohepatitis Trial Screening Cohort Mazen Noureddin, Jörn M. Schattenberg, Rashmee Patil, Elizabeth W. Brombosz, Gražina Binkauskiene, Michelle Mazuranic, Laura Ladron de Guevara Cetina, Marcelo Kugelmas, Aasim Sheikh, John Poulos, Sudha Kodali, Brian P. Lee, Juan Pablo Arab, Naim Alkhouri Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Association of a Reported Penicillin Allergy Label With Clinical Outcomes in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Kanyaphak Charnpatanakorn, Preenapun Saokhieo, Ben Thiravetyan, Allan Bueso, Ahmad Anouti, Apichat Kaewdech, Surapon Nochaiwong, Luis Antonio Díaz, Juan Pablo Arab, Jonathan A. Bernstein, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Aspirin eugenol ester attenuates alcoholic liver injury via the NRF2/SLC7A11/GPX4 pathway-mediated ferroptosis suppression Zhi-Jie Zhang, Qi Tao, Ji Feng, Li-Ping Fan, Dong-Shuai Shen, Ya-Jun Yang, Jian-Yong Li Phytomedicine.2026; : 158848. CrossRef
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0444. CrossRef
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum Han Ah Lee, Gi-Ae Kim, Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0367. CrossRef
Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021. Authors' Reply Pojsakorn Danpanichkul, Donghee Kim, Markos Kalligeros, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 1080. CrossRef
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, Cynthia Valério, Rodrigo Oliveira Moreira, Mónica Acevedo, Javier Brahm, Nelia Hernández, Adrian Gadano, Claudia P. O Annals of Hepatology.2025; 30(2): 101903. CrossRef
Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy, and Addiction Management. Authors' Reply Luis Antonio Díaz, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 61(7): 1256. CrossRef
Implementing public health policy to tackle alcohol-related harms Pojsakorn Danpanichkul, Karn Wijarnpreecha The Lancet Public Health.2025; 10(5): e350. CrossRef
Alcohol-Associated Liver Disease and Risk Stratification for Hepatocellular Carcinoma: A Comprehensive Review Jaeyoun Choi, Hyun-seok Kim Current Hepatology Reports.2025;[Epub] CrossRef
Public Health Policies and Strategies to Prevent Alcohol-Related Morbidity and Mortality Roba El Zibaoui, Luis Antonio Díaz, Francisco Idalsoaga, Juan Pablo Arab Current Hepatology Reports.2025;[Epub] CrossRef
Tetramethylpyrazine: A fermented alcohol product that mitigates alcoholic liver disease in mice Qing Pu, Han Gao, Dake Xiao, Manyuan Wang, Zhiyun Yang, Qiang He, Min Liu, Xuejin Zhu, Tao Pan, Zhitao Ma, Jiabo Wang, Yao Liu Free Radical Biology and Medicine.2025; 236: 160. CrossRef
Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020) Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanida Auttapracha, Shu-Yen Chan, Do Han Kim, Thanawin Pramotedham, Kanita Mankan, Chanokporn Puchongmart, Juan Pablo Arab, Luis Antonio Diaz, Jorge D. Machicado, Michael B. Wallace, Karn Wijarnpreecha Pancreatology.2025; 25(4): 508. CrossRef
Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease Luis Antonio Díaz, Summer Collier, Jeffrey Yin, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 62(7): 692. CrossRef
Osteoporosis is associated with increased CVD mortality and all-cause mortality in alcohol-consuming individuals: A cohort study using data from NHANES Xiaoqin Qu, Jingcheng Jiang, Qian Wu, PLOS One.2025; 20(6): e0327180. CrossRef
Fabrication of camptothecin and gold nanoparticles encapsulated liposomes for synergic anticancer therapy in liver cancer cells Hengyang Wang, Jingjian Ding, Tao Wang, Kongliang Luo Particulate Science and Technology.2025; 43(6): 1002. CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul Liver International.2025;[Epub] CrossRef
Social determinants of alcohol and tobacco use among Hispanic adolescents: a scoping review Kazi Priyanka Silmi, Victoria Castillo, Nallely Segura, Nayeli Carrillo Cervantes, Yailene Perez, Aubrey Valenzuela, Erika A. Pugh, Jennifer B. Unger, Marybel R. Gonzalez Frontiers in Psychiatry.2025;[Epub] CrossRef
MetALD: new insights and unraveling therapeutic potential Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis Bernardo de Faria Moraes, Gabriel André Pedral Diniz Leite, Gustavo André Pedral Diniz Leite, Igor Boechat Silveira, Nathália Veloso Lana, Guilherme Grossi Lopes Cançado Drug and Alcohol Dependence.2025; 275: 112840. CrossRef
Portal hypertension in alcohol-associated hepatitis: harmless and the reflection of systemic inflammation? Karim Gebara, Lionel Moulis, Joana Pissarra, Benjamin Rivière, Georges-Philippe Pageaux, José Ursic-Bedoya Clinics and Research in Hepatology and Gastroenterology.2025; 49(8): 102668. CrossRef
Patterns and Outcomes of Alcoholic Liver Disease (ALD) in Oman: A Retrospective Study in a Culturally Conservative Context Said A. Al-Busafi, Thuwiba A. Al Baluki, Ahmed Alwassief Livers.2025; 5(3): 38. CrossRef
Alcoholic liver disease: Mechanistic insights and therapeutic potential of traditional Chinese medicine through preclinical and clinical evidence Ke Wu, Long Zhao, Tiangang Wang, Jiayue Yang, Yueshui Zhao, Fukuan Du, Yu Chen, Shuai Deng, Jing Shen, Zhangang Xiao, Jingwen Liu, Ruhan Yang, Xi Li, Hua Li, Wanping Li, Xiaobing Li, Yuhong Sun, Li Gu, Xu Wu, Mingxing Li Journal of Ethnopharmacology.2025; 353: 120465. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Comparative effectiveness of digital versus face-to-face cognitive behavioral therapy for alcohol use disorder: a systematic review and meta-analysis Ji Eun Kim, Jiyeong Kim, Nayeon Choi, Sang Kyu Lee, Hong Seok Oh, Sungwon Roh Psychological Medicine.2025;[Epub] CrossRef
Alcohol use and cirrhosis in women: An underestimated risk P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef
A Higher Risk of Liver Cancer in Alcoholic Fatty Liver Disease than in Non-Alcoholic Fatty Liver Disease: an Analysis of the TriNetX Dabatase Ling-Hui Chang, Sheng-You Su, Chun Lee, Chao-Yu Hsu Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply Luis Antonio Díaz, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1241. CrossRef
Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications Luyuan Chang, Yang Liu, Haipeng Li, Jiaqi Yan, Wenzong Wu, Nuo Chen, Chunyu Ma, Xinyi Zhao, Juan Chen, Jing Zhang Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease Wei Zhang, Soo Young Hwang, Jay Luther Current Gastroenterology Reports.2025;[Epub] CrossRef
A multi-omics approach combining causal inference and in vivo validation identifies key protein drivers of alcohol-associated liver disease Qingyi Zhou, Xuan Ma, Qianqian Cui, Lei Zhang, Chao Yao, Zilu Zhang, Xiaoli Wang, Liang Chu Frontiers in Immunology.2025;[Epub] CrossRef
Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy Afreen Usmani, Mohd Aftab Siddiqui, Anuradha Mishra, Rania I.M. Almoselhy, Ambreen Shoaib, Mirunalini Gobinath, Mohd Nazam Ansari Medical Oncology.2025;[Epub] CrossRef
Background/Aims Multi-society experts proposed the adoption of new terminology, metabolic dysfunctionassociated steatotic liver disease (MASLD) and steatotic liver disease (SLD). We studied the current prevalence of SLD and its subcategories in the US.
Methods Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography. SLD and its subcategories, including MASLD, metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD), were categorized according to consensus nomenclature.
Results The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1). The prevalence of SLD and MASLD showed a statistically insignificant decrease during COVID-19, while ALD increased without significance. In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era. The proportion of advanced fibrosis and cirrhosis in individuals with ALD was two-fold higher than MASLD and MetALD, largely due to increases during the COVID-19 era.
Conclusions While the prevalence of SLD and its subcategories remained stable, there was a significant increase in advanced fibrosis among SLD individuals during the COVID-19 era, with ALD having a proportion of advanced fibrosis and cirrhosis that was twice as high as MASLD and MetALD.
Citations
Citations to this article as recorded by
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé Clinical Gastroenterology and Hepatology.2026; 24(3): 688. CrossRef
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Sisi Yang, Zhenxuan Ma Clinical and Molecular Hepatology.2026; 32(1): e4. CrossRef
Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invern Alimentary Pharmacology & Therapeutics.2026; 63(4): 494. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 662. CrossRef
Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding Ultrasound in Medicine & Biology.2026; 52(1): 227. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 752. CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha Digestive Diseases and Sciences.2026; 71(6): 2165. CrossRef
SGLT‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes Do Han Kim, Donghyun Ko, Vincent L. Chen, Jose A. Porres, Carlos Elizondo Alatorre, Luis M. Nieto, Pedro Palacios Argueta, Paul T. Kröner, Frank J. Lukens, Donghee Kim, Raffi Karagozian, Meena B. Bansal, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Serum uric acid and the risk of MASLD in Americans: A cross-sectional study combined with Mendelian randomization and network toxicology analysis Xusheng Zhang, Wenyan Zhou, Bendong Chen, Qi Wang Medicine.2026; 105(1): e46841. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD Pojsakorn Danpanichkul, Hanna Blaney, Javiera Perelli, Paula Huerta, Francisco Idalsoaga, Marco Arrese, Juan Pablo Arab, Rohit Loomba, Luis Antonio Díaz Metabolism and Target Organ Damage.2026;[Epub] CrossRef
The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis Yuan Zhao, Xuanhui Li, Jiacheng Cheng, Dongyu Hu, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li Frontiers in Medicine.2026;[Epub] CrossRef
Diagnostic value of LPRI for assessing advanced liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease Min Wang, Huaxiao Chen, Jiaen Yang, Xueting Huang, Runyan He, Baohui Pei, Xiaolu Wu, Yanneng Kang, Longhao Xu BMC Gastroenterology.2026;[Epub] CrossRef
The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review Aoun Laurence, Shruti M. Gandhi, Eric S. Nylen, Sabyasachi Sen Endocrine Practice.2026; 32(6): 1001. CrossRef
LiverRisk score (LRS) predicts long-term liver-related outcomes in a cohort of Veterans without evidence of liver disease Ruben Hernaez, Yan Liu, Miquel Serra-Burriel, Kavish R. Patidar, Adrià Juanola, Isabel Graupera, Elisa Pose, Núria Fabrellas, Avegail G. Flores, Jennifer R. Kramer, Fasiha Kanwal, Pere Gines Hepatology.2026; 84(3): 805. CrossRef
Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease Na Young Lee, Myeung Gi Choi, Ho Jae Ryu, Young Jin Min, Seon Min Kim, Yeonseok Chung, Bo Kyung Koo, Yun Pyo Kang, Won Kim, Ja Hyun Koo Advanced Science.2026;[Epub] CrossRef
Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis Maria Tampaki, Vasileios Lekakis, Christos Chologkitas, Stergios Α. Polyzos, Evangelos Cholongitas Current Obesity Reports.2026;[Epub] CrossRef
Alcohol consumption exacerbates high-fat diet-mediated disruptions in myelopoiesis and osteoclastogenesis in mouse models of metabolic dysfunction-associated liver diseases Hami Hemati, Madison B. Blanton, Lauren Rutt, Nicholas Keiran, Rebecca Geron, Florence Lima, Rebecca L. McCullough, Ilhem Messaoudi Frontiers in Endocrinology.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(2): e194. CrossRef
Correspondence to letter to the editor on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States” Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(2): e246. CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and overactive bladder: A cross-sectional study Shengqi Zheng, Xu Cui, Longyao Xu, Hong Chen, Liang Zheng, Chaoming Zhou Continence.2026; 18: 102466. CrossRef
Association of alcohol intake with pre-sarcopenia risk in steatotic liver disease: a dose-dependent relationship Qiyang Chen, Ruifang Xu, Linxue Qian, Yujiang Liu, Xiangdong Hu European Journal of Gastroenterology & Hepatology.2026; 38(9): 1074. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Surgically confirmed severe endometriosis is associated with lower risk of steatotic liver disease: Evidence of estrogen‐linked hepatic–reproductive crosstalk Jung Hyun Park, Keungmo Yang, Hyun Yang, Si Hyun Bae, Mee‐Ran Kim, Jaejun Lee International Journal of Gynecology & Obstetrics.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Burden of cardiovascular complications in steatotic liver disease in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(3): e326. CrossRef
Liver fibrosis burden and risk of incident arrhythmia in metabolic dysfunction-associated steatotic liver disease Keungmo Yang, Seung Hyun Kim, Jaejun Lee, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Hong Soo Kim, Yongeun Cho, Tom Ryu Scientific Reports.2026;[Epub] CrossRef
From steatosis to metastasis: microenvironmental reprogramming of the liver in metabolic dysfunction-associated steatotic liver disease Gyu Jeong Cho, Sun Myoung Kim, Yoon Mee Yang, Ekihiro Seki Clinical and Molecular Hepatology.2026; 32(3): 1135. CrossRef
Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver out Donghee Kim, Anoushka Shenoy, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(3): 1441. CrossRef
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications Luis Antonio Díaz, Elisa Pose, Mads Israelsen, Rohit Loomba Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026; 41(9): 2913. CrossRef
Integrated analyses of in vivo mouse models and liver organoids reveal MFG-E8-mediated protection against hepatocyte injury Heng-Fu Bu, Qianming Jiang, Hua Geng, Saravanan Subramanian, Nazeer Hussain Khan, Xiao Wang, Xiao-Di Tan American Journal of Physiology-Gastrointestinal and Liver Physiology.2026; 331(3): G384. CrossRef
Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis Hana Park, Ji Young Lee, Ja Eun Koo, Jong Soo Lee, Sungwon Park, Hye Won Park, Hye-Sook Chang, Hong-Kyu Kim, Jaewon Choe, Ju Hyun Shim Gut and Liver.2026; 20(5): 880. CrossRef
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0444. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States—Author's Reply Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 1059. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng Clinical and Molecular Hepatology.2025; 31(2): 620. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021” Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab Clinical and Molecular Hepatology.2025; 31(2): e200. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco Journal of Clinical Medicine.2025; 14(11): 3821. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
The association between sedentary behavior and MASLD in overweight and obese adults: investigating the role of inflammatory markers using NHANES data (2017–March 2020) Zehong Zhou, Linfang Li, Chusi Wang, Shiqi Li, Pengfei Chen, Jiesheng Huang, Ming Peng Frontiers in Nutrition.2025;[Epub] CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e268. CrossRef
Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1100. CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari Inflammopharmacology.2025; 33(9): 5583. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD Tom Ryu, Yeon Joo Seo, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang International Journal of Molecular Sciences.2025; 26(20): 10061. CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver disease and hepatocellular carcinoma (HCC). Besides the population with obesity, MASLD can also be found in lean populations, accounting for 13% of the global population, especially Asians. Notably, individuals with lean MASLD face equal or higher overall mortality rates compared to their non-lean counterparts. Risk modifiers encompass advanced age, hepatic fibrosis, and type 2 diabetes mellitus (T2DM). Moreover, the population with lean MASLD is associated with an increased risk of HCC, while their non-lean counterparts are more prone to cardiovascular outcomes and T2DM. Existing evidence indicates a similar risk of liver-related events and extrahepatic cancer between the two groups. However, MASLD-related genetic variants, such as PNPLA3 and TM6SF2, did not significantly affect mortality between the two populations. Still, underreporting alcohol consumption and regional representation limits the study’s comprehensiveness. Longitudinal studies and mechanistic explorations are needed to understand differences in lean versus non-lean MASLD populations. This review highlights the need for awareness and tailored interventions in managing MASLD, considering lean individuals’ unique risks.
Citations
Citations to this article as recorded by
Effects of Body-Weight Changes on the Risk of New-Onset Diabetes in Individuals With Non-Diabetic Metabolic Dysfunction-Associated Steatotic Liver Disease Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Geum-Youn Gwak Journal of Korean Medical Science.2027;[Epub] CrossRef
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 662. CrossRef
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim Gut and Liver.2026; 20(1): 107. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Poor Sensitivity of the Fatty Liver Index Among Lean Individuals Mohammed Rifat Shaik, Yaron Rotman American Journal of Gastroenterology.2026; 121(9): 2231. CrossRef
Association of Metabolic Dysfunction–Associated Steatotic Liver Disease With Features of Cerebral Small‐Vessel Disease on Magnetic Resonance Images: A Large Cross‐Sectional Study Yaqin Wang, Kui Chen, Changfa Wang, Zhongyang Hu, Xiaoling Zhu, Lei Liu Journal of the American Heart Association.2026;[Epub] CrossRef
Epigenetic Aging Biomarkers in Lean MAFLD Ziyan Pan, Shadi Zerehpoosh, Mohammed Eslam Liver International.2026;[Epub] CrossRef
Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation Sherlot Juan Song, Yiwei Liu, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Gut.2026; : gutjnl-2026-338216. CrossRef
Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter Lanlan Chen, Paul Horn, Frank Tacke Diabetes, Obesity and Metabolism.2026; 28(S2): 46. CrossRef
Disparities in Liver Transplantation Among Native Americans and Hispanic Individuals: Insights from a Southwest Region Center in the United States of America Anandalakshmi Ponnaluri, Pooja Rangan, Pojsakorn Danpanichkul, Andrew Bell, Rebecca Postagate, Moises Ilan Nevah Rubin, Michael B. Fallon, Karn Wijarnpreecha Journal of Clinical Medicine.2026; 15(3): 953. CrossRef
Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119–AMPK signaling Yangzheng He, Jing Li, Zhigang Wen, Yong Sun, Liufeng Zheng, Hongyan Li, Zeyuan Deng Journal of Advanced Research.2026;[Epub] CrossRef
Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks Zhen Sun, Jinhao Li, Xuefei Yu, Yuchen Jiang, Jiaojiao Zheng, Yuan Ouyang, Ming Guan, Xuan Deng, Bo Li, Haojie Jin Clinical Gastroenterology and Hepatology.2026; 24(9): 2486. CrossRef
Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis Omar Al Ta'ani, Yahya Alhalalmeh, Mohammad Alabdallat, Abdallah Naser, Saqr Alsakarneh, Saleh Saleh, Pojsakorn Danpanichkul, Dushyant Dahiya Singh, Basile Njei, Nikki Duong Clinical and Translational Gastroenterology.2026; 17(4): e00974. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2026; 32(2): 646. CrossRef
Body Roundness Index and All‐Cause Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Dual‐Cohort Study Zijian Li, Shishu Yin, Jian Cui, Jinxin Shi, Fuhai Ma, Tianming Ma, Qi An, Tao Yu, Danian Tang, Xianglong Cao, Gang Zhao Diabetes, Obesity and Metabolism.2026; 28(6): 4961. CrossRef
Central obesity measured by weight-adjusted waist index is associated with lean MASLD Ziteng Wang, Wentao Tan, Zhe Yu, Herui Wei, Jing Luo, Wen An, Mengqi Li, Qi Gao, Lijuan Sun, Aqian Song, Lingling He, Jiali Ma, Fan Xiao, Hong Liu, Hui Zhong, Hongshan Wei Clinics and Research in Hepatology and Gastroenterology.2026; 50(5): 102822. CrossRef
Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Wan‐Yu Wang, Shu‐Fen Liao, Ching‐Wen Chang Health Science Reports.2026;[Epub] CrossRef
Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026; 170(7): 1571. CrossRef
Outcomes of liver and cardiovascular metabolic diseases among lean vs non-lean individuals with metabolic dysfunction-associated steatotic liver disease Mexan Mapouka, Evariste Pabingui, Nkengeh N Tazinkeng, Milkessa Gurmessa, Ulrich Vickos, Nkafu Bechem Ndemazie, Serge Magloire Camengo Police World Journal of Gastroenterology.2026;[Epub] CrossRef
Arachidonoyl-taurine is elevated in human MASLD and protects against hepatic steatosis and inflammation in preclinical models Katharina B. Kuentzel, Samuel A.J. Trammell, Anna S. Hassing, Ivan Bradić, Michelle Damgaard, Emma B. Fals, Katja T. Michler, Matthew Dooley, Jens C.B. Jacobsen, Malte P. Suppli, Mikkel P. Werge, Cameron J. Mitchell, Nicolai J. Wewer Albrechtsen, Lise L. Journal of Hepatology.2026; 85(3): 479. CrossRef
Predictive value of TyG-BMI, CTI, and SII in identifying metabolic dysfunction-associated steatotic liver disease among patients with type 2 diabetes mellitus Yue Chen, Yayu Lai, Qu Xiang, Li Fan, Xingyu Chen, Jin Gao, Qingfeng Cheng, Xu Luo Frontiers in Nutrition.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression Ludovico Abenavoli, Anna Giulia Loricchio, Ivo Lopez, Domenico Morano, Abdulrahman Ismaiel, Dan Lucian Dumitrascu, Francesco Luzza Medicina.2026; 62(5): 986. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y Journal of Biochemical Technology.2026; 17(2): 30. CrossRef
MASLD prevalence, incidence and global aspects Sarah H. Wild, Jeffrey V. Lazarus, C. Wendy Spearman, Ponsiano Ocama, Josh Bilson, Xiao-Dong Zhou, Ming-Hua Zheng, Christopher D. Byrne Diabetologia.2026; 69(11): 3034. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment Zhifu Cui, Xiaxia Du, Felix Kwame Amevor, Yaoyao Xia, You Yang, Lingbin Liu MedComm.2026;[Epub] CrossRef
Review of Obesity and Cancer Zi-Li Huang, Wen-Tao Song, Xiu-Yan Huang JAMA.2026; 336(6): 519. CrossRef
Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality Eileen Laurel Yoon, Hyo Young Lee, Jonghyun Lee, Joo Hyun Oh, Inseok Hwang, Chan Hee Park, Sejung Kim, Huiyul Park, Ae Jeong Jo, Dae Won Jun Gut.2026; : gutjnl-2026-339142. CrossRef
Uric Acid-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but Not Fibrosis in Nonobese Adults: A NHANES 2017–2020 Study Linwan Li, Xiang’an Zhao Metabolic Syndrome and Related Disorders.2026; 24(8): 383. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes? Aftab Ala, Ponnusamy Saravanan Clinical Medicine.2026; 26(4): 100629. CrossRef
Capturing systemic disease burden in MASLD: Toward integrated liver–kidney–cardiovascular economic models: Reply to correspondence on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic live Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice Clinical and Molecular Hepatology.2026; 32(3): e447. CrossRef
Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver out Donghee Kim, Anoushka Shenoy, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(3): 1441. CrossRef
Toward Precision Medicine in MASLD: Evolution of Disease Subtyping Ting Feng, Jiaming Li, Xiaoyi Ma, Junzhao Ye Seminars in Liver Disease.2026; 46(02): 196. CrossRef
Reconciling definitions, phenotypes and outcomes in lean metabolic dysfunction-associated steatotic liver disease: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver o Shanshan Wu Clinical and Molecular Hepatology.2026; 32(3): 1437. CrossRef
Cholesterol metabolism implications for cancer and therapy Lianghan Lin, Peipei Song, Wei Xie, Jianping Guo The Innovation Nutrition.2026; 1(2): 100025. CrossRef
The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, ch Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Dae Won Jun Clinical and Molecular Hepatology.2026; 32(3): e389. CrossRef
Cryptogenic steatotic liver disease reveals hidden liver risk in metabolically silent lean individuals Pojsakorn Danpanichkul, Ju Dong Yang Gut.2026; : gutjnl-2026-339978. CrossRef
Red Cell Distribution Width as an Independent Prognostic Biomarker in MASLD Tom Ryu, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang Antioxidants.2026; 15(9): 1065. CrossRef
Global landscape of clinical trials and therapeutic targets in metabolic dysfunction-associated steatotic liver disease: an integrative multi-omics analysis Yanxi Mu, Weixiong Zhu, Zhihao Wei, Zhao Guo, Haofei Chen, Yusheng Cheng, Wence Zhou Journal of Endocrinological Investigation.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Childhood: From Disease Heterogeneity to Personalized Care Maria Rogalidou, Christina Kanaka-Gantenbein Journal of Personalized Medicine.2026; 16(9): 464. CrossRef
Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status Dong Yun Kim, Kyu-Na Lee, Kyung-Do Han, Beom Kyung Kim Biomedicines.2026; 14(9): 1985. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Outcomes in Atrial Fibrillation Pojsakorn Danpanichkul, Yanfang Pang, Kwanjit Duangsonk, Nithila Sivakumar, Primrose Tothanarungroj, Ahmad Anouti, Matheus Souza, Omar Y. Mousa, Thomas G. Cotter, Donghee Kim, Suthat Liangpunsakul, Chayakrit Krittanawong, Mazen Noureddin The American Journal of Medicine.2026;[Epub] CrossRef
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0444. CrossRef
Waist-to-height ratio reveals hidden metabolic risk in lean individuals with MASLD Ziteng Wang, Wentao Tan, Jing Luo, Herui Wei, Wen An, Mengqi Li, Qi Gao, Lijuan Sun, Lingling He, Jiali Ma, Fan Xiao, Hui Zhong, Hongshan Wei Clinical Nutrition ESPEN.2026; 76: 105064. CrossRef
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five‐Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Seung Up Kim, Su Jong Yu, Pil Soo Sung Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum Han Ah Lee, Gi-Ae Kim, Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0367. CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban Clinical and Experimental Medicine.2025;[Epub] CrossRef
Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity Yajie Liu, Ruilin Wang BMC Gastroenterology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2025; 40(8): 1919. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Alimentary Pharmacology & Therapeutics.2025; 62(3): 244. CrossRef
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114. CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang Frontiers in Endocrinology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann Hepatology International.2025; 19(6): 1347. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka Polish Annals of Medicine.2025; : 1. CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso Frontiers in Gastroenterology.2025;[Epub] CrossRef
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero International Journal of Molecular Sciences.2025; 26(23): 11425. CrossRef
Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch Livers.2025; 5(4): 65. CrossRef
Intestinal NLRP3 Deficiency Exacerbates MASLD in Male Mice via Reduced Butyrate Production Li Chen, Jing Li, Hao Yu Jia, Chun Liu, Shan Shan Li, Feng Shang Zhu, Chang Qing Yang Journal of Digestive Diseases.2025; 26(11-12): 544. CrossRef
PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology Ralf Weiskirchen, Amedeo Lonardo Journal of Translational Genetics and Genomics.2024; 8(4): 355. CrossRef
Telomere length and metabolic dysfunction-associated steatotic liver disease risk and progression: A systematic review and meta-analysis Chunfeng Sun, Ping Qiu, Shuo Huang, Qihan Luo, Qing Ma, Piao Hu, Fangming Chen, Hongyan Wu, Chunxiao Chen Experimental Gerontology.2026; 214: 113036. CrossRef
Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah iLIVER.2026; 5(1): 100222. CrossRef
Fibrosis and Perinatal Features Correlated with Telomere Shortening in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease Maria Rita Braghini, Salvatore Daniele Bianco, Marzia Bianchi, Giulia Andolina, Antonella Mosca, Cristiano De Stefanis, Michela Piccione, Paola Francalanci, Clara Balsano, Luca Miele, Tommaso Mazza, Anna Alisi Life.2026; 16(7): 1068. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Backgrounds/Aims The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based trends in HCC and biliary tract cancers-related mortality in US adults with a focus on disease burden.
Methods We performed a population-based analysis using the US national mortality records from 2018 to 2023. We identified HCC and biliary tract cancer using appropriate ICD-10 codes. Temporal trends in mortality were calculated by joinpoint analysis with annual percentage change (APC).
Results Annual age-standardized mortality from HCC decreased steadily with an APC of –1.4% (95% confidence interval [CI]: –2.0% to –0.7%). While there was a linear increase in intrahepatic cholangiocarcinoma-related mortality (APC: 3.1%, 95% CI: 1.2–4.9%) and ampulla of Vater cancer-related mortality (APC: 4.1%, 95% CI: 0.5–7.9%), gallbladder cancer-related mortality decreased (APC: –1.9%, 95% CI: –3.8% to –0.0%). Decreasing trends in mortality from HCC were noted in males, not females. HCC-related mortality decreased more steeply in racial and ethnic minority individuals compared with non-Hispanic White individuals. Racial and ethnic differences in trends in mortality for biliary tract cancers depended on the malignancy’s anatomical site.
Conclusions While the annual mortality for HCC and gallbladder cancer demonstrated declining trends, ICC- and AVC-related mortality continued to increase from 2018 to 2023. Although racial and ethnic minority individuals in the US experienced disproportionately higher HCC and biliary tract cancer, recent declines in HCC may be primarily due to declines among racial and ethnic minority individuals and males.
Citations
Citations to this article as recorded by
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2026; 24(6): 1644. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 752. CrossRef
Sex Differences in Liver Cancer Mortality Trends in the US: Role of Cancer Type, Aetiology, and Birth Cohort Ugo Fedeli, Sara Battistella, Elisa Pinto, Veronica Casotto, Alberto Zanetto, Chiara Suraci, Elena Marchese, Andrew M. Moon, Francesco Paolo Russo Liver International.2026;[Epub] CrossRef
Moving beyond Ultrasound for Hepatocellular Carcinoma Surveillance in High-Risk Patients with Chronic Hepatitis B Hae Lim Lee Gut and Liver.2026; 20(2): 174. CrossRef
Spatiotemporal trends, demographic disparities, and predictions to 2040 in gastrointestinal cancer mortality in the United States Maolang He, Jingyi Zhang, Shangqi Wang, Kainan Xing, Yanxin Zhao, Jianzhen Chen, Xi Zhang, Yong Zheng, Shuxin Tian BMC Public Health.2026;[Epub] CrossRef
Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(2): e194. CrossRef
Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers Gabriele Saccu, Sharmila Fagoonee Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of Hepatocellular Carcinoma: A Network and Individual Patient Data (IPD) Meta-Analysis Abdullah Esmail, Yazan Hamdaneh, Nour Mustafa, Ebtesam Al-Najjar, Zaid Alabed, Hikmat Abdel-Razeq, Asem Mansour, Maen Abdelrahim Cancers.2026; 18(13): 2118. CrossRef
Contemporary global epidemiology of cirrhosis Preenapun Saokhieo, Thanida Auttapracha, Pojsakorn Danpanichkul, Yanfang Pang, Liu Yang, Amit G. Singal, Donghee Kim, Karn Wijarnpreecha Hepatology Communications.2026;[Epub] CrossRef
Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis Volker Rudat, Jing Li, Ruping Zhao, Yanyan Shi, Liang Huang, Maixuan Qiu, Jun Li, Andrew X. Zhu, Yiqun Yan Radiation Oncology.2026;[Epub] CrossRef
Global Burden, Trends, and Inequalities of Gallbladder and Biliary Tract Cancer, 1990–2021: A Decomposition and Age–Period–Cohort Analysis Sen Lei, Guizhong Huang, Xiaohui Li, Pu Xi, Zehui Yao, Xiaojun Lin Liver International.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults Donghee Kim, Won Kim, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(1): e5. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023” Ilona Argirion Clinical and Molecular Hepatology.2025; 31(1): 286. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Integrating expert knowledge with machine learning for AI-based stroke identifications and treatment systems Taddesse kassu Yimenu, Abebe Belay Adege, Sofonias Yitagesu Techan DIGITAL HEALTH.2025;[Epub] CrossRef
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e268. CrossRef
Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023 Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e277. CrossRef
Epidemiological trends and burden of gallbladder and biliary tract cancer in Belt and Road Initiative countries: A comprehensive analysis from the Global Burden of Disease 2021 database Hao Wu, Qian-Qian Feng, Jian-Hui Li, Hai-Yang Xie, Shi-Gui Yang, Shu-Sen Zheng Hepatobiliary & Pancreatic Diseases International.2025; 24(6): 666. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Construction and validation of a novel prognostic model for postoperative patients with stage I intrahepatic cholangiocarcinoma: a population-based study Xiaomeng Yao, Xinru Fan, Qing Wang, Huabang Zhou, Hui Wang, Heping Hu Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions Yang Zhang, Yixiang Gu, Ming Zhan, Linhua Yang, Hui Wang Molecular Biomedicine.2025;[Epub] CrossRef
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
Citations
Citations to this article as recorded by
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu Clinical Pharmacology & Therapeutics.2026; 119(2): 336. CrossRef
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trial Songyue Liu, Yangzhi Yin, Hongmei Yang, Lufan Sun, Jun Wang, Ying Zhou, Lin Guan, Liying Xing, Ziyi Xie, Ning Ye, Chuan Yang, Wei Miao, Shiyu Zhou, Yao Yu, Zhi Li, Xiangyu Tan, Caiyu Zhang, Chenhua He, Yueting Liu, Yifei Chen, Guozhe Sun, Xiaofan Guo BMC Medicine.2026;[Epub] CrossRef
Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar Aisha Al-Khinji, Dhafer Malouche, Noof Al-Thani, Azza Mustafa, Jazeel Abdulmajeed, Mohamed Ghaith Al-Kuwari Frontiers in Medicine.2026;[Epub] CrossRef
Effect of intermittent fasting on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease Qinhan Liu, Ling Zhang, Yaomin Wang, Jun Li, Yaling Li Clinics and Research in Hepatology and Gastroenterology.2026; 50(7): 102875. CrossRef
Hepatic fibro-inflammation measured by magnetic resonance imaging iron-corrected T1 predicts extrahepatic cancer risk: a UK Biobank study Hye Yeon Chon, Seok-Jae Heo, SungA Bae, Tae Seop Lim, Ja Kyung Kim Clinical and Molecular Hepatology.2026; 32(3): 1349. CrossRef
Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy Benjamin Blaske, Michael Ward, Ragesh Babu Thandassery World Journal of Hepatology.2026;[Epub] CrossRef
Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction Ángel Arturo López-González, Emilio Martínez-Almoyna Rifá, Hernán Paublini Oliveira, Cristina Martorell Sánchez, Pedro Juan Tárraga López, José Ignacio Ramírez-Manent Life.2025; 15(1): 116. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
Non alkolik yağlı karaciğer hastalığı ile kafein alımı arasındaki ilişki İzel Akkaya, İlknur Gökçe Yıldırım Sağlık Profesyonelleri Araştırma Dergisi.2025; 7(1): 47. CrossRef
Advances in humanoid organoid-based research on inter-organ communications during cardiac organogenesis and cardiovascular diseases Baoqiang Ni, Lingqun Ye, Yan Zhang, Shijun Hu, Wei Lei Journal of Translational Medicine.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Investigating the Mechanisms of Lycii fructus in Treating Nonalcoholic Fatty Liver Disease and Diabetes Comorbidity Through Network Pharmacology and Molecular Dynamics Peng Sun, Jiahui Song, Yang Liu, Xiujing Li, Yiming Zhang, Yuxing Zhou, Wei Gong Food Science & Nutrition.2025;[Epub] CrossRef
Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017–2020 Database Tianhao Wu, Lu Li, Yayuan Mei, Peizhen Lv, Jiawei Cui, Lin Liu, Yuemin Nan, Ang Li, Yu-Chen Fan Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Extrahepatic Comorbidities Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease; A Tertiary Hospital Experience Masoudreza Sohrabi, Mozhdeh Mosalli, Parvin Hassanzadeh, Somayeh Bahrami, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Farhad Zamani Middle East Journal of Digestive Diseases.2025; 17(2): 96. CrossRef
Causal Relationship between Psoriasis and Non-Alcoholic Fatty Liver Disease: A Bidirectional Two-Sample Mendelian Randomization Study 恒 杨 Advances in Clinical Medicine.2024; 14(04): 101. CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi BMC Endocrine Disorders.2024;[Epub] CrossRef
Masquerading Spleen: A Perplexing Case of Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma Noriko Ikeda, Yujo Kawashita, Masaki Tateishi, Takashi Ueda, Junzo Yamaguchi, Yasuo Washida, Yoichi Hachitanda Cureus.2024;[Epub] CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease Maryam K. Ibrahim, Tracey G. Simon, Mary E. Rinella Clinics in Liver Disease.2023; 27(2): 251. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Diabetes and cirrhosis: Current concepts on diagnosis and management Laurent Castera, Kenneth Cusi Hepatology.2023; 77(6): 2128. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Polycystic ovary syndrome in pediatric obesity and diabetes Elena DONDI, Maria TUFANO, Maria C. VIGONE, Laura LUCACCIONI, Gabriella POZZOBON, Graziamaria UBERTINI, Enza MOZZILLO, Maurizio DELVECCHIO Minerva Pediatrics.2022;[Epub] CrossRef
Mouse liver injury induces hepatic macrophage FGF23 production Pradeep Kumar, Yunshan Liu, Yang Shen, Jacquelyn J. Maher, Francesca Cingolani, Mark J. Czaja, Matias A Avila PLOS ONE.2022; 17(3): e0264743. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Life.2022; 12(8): 1189. CrossRef
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Clinical and Molecular Hepatology.2022; 28(4): 725. CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Biomedicines.2022; 10(10): 2375. CrossRef
Intestinal microbiota in the treatment of metabolically associated fatty liver disease Ji-Shuai Wang, Jin-Chun Liu World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef
A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review Chowdhury F Zaman, Jakia Sultana, Proma Dey, Jui Dutta, Sadia Mustarin, Nuzhat Tamanna, Aditi Roy, Nisha Bhowmick, Mousumi Khanam, Sadia Sultana, Selia Chowdhury, Farjana Khanam, Md Sakibuzzaman, Priyata Dutta Cureus.2022;[Epub] CrossRef
The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials Carmine Izzo, Monica Annunziata, Giuseppe Melara, Roberta Sciorio, Marcello Dallio, Mario Masarone, Alessandro Federico, Marcello Persico Nutrients.2021; 13(3): 933. CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study Yewan Park, Dong Hyun Sinn, Joo Hyun Oh, Myung Ji Goh, Kyunga Kim, Wonseok Kang, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Geum‐Youn Gwak Hepatology.2021; 74(6): 2988. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Non‑alcoholic fatty liver disease and hematologic manifestations (Review) Vlad Pădureanu, Dalia Dop, Alice Drăgoescu, Rodica Pădureanu, Anca Mușetescu, Laurențiu Nedelcu Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression Marcello Dallio, Moris Sangineto, Mario Romeo, Rosanna Villani, Antonino Davide Romano, Carmelina Loguercio, Gaetano Serviddio, Alessandro Federico International Journal of Molecular Sciences.2021; 22(1): 436. CrossRef
Nutraceutical correction in the complex non-drug treatment of metabolic syndrome L.G. Agasarov, T.V. Apkhanova, V.N. Sergeev, A.D. Fesun, M.M. Krukova, V.A. Vasilyeva, D.B. Kulchitskaya, T.V. Konchugova, G.A. Puzyreva, M.Yu. Yakovlev Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury.2021; 98(4): 25. CrossRef
First
Prev
